Akiskal Hagop S, Benazzi Franco
International Mood Center, University of California at San Diego, VA Psychiatry Service, 116A, 3350 La Jolla Village Drive, 92161, USA.
J Affect Disord. 2006 May;92(1):45-54. doi: 10.1016/j.jad.2005.12.035. Epub 2006 Feb 20.
Presently it is a hotly debated issue whether unipolar and bipolar disorders are categorically distinct or lie on a spectrum. We used the ongoing Ravenna-San Diego Collaboration database to examine this question with respect to major depressive disorder (MDD) and bipolar II (BP-II).
The study population in FB's Italian private practice setting comprised consecutive 650 outpatients presenting with major depressive episode (MDE) and ascertained by a modified version of the Structured Clinical Interview for DSM-IV. Differential assignment of patients into MDD versus BP-II was made on the basis of discrete hypomanic episodes outside the timeframe of an MDE. In addition, hypomanic signs and symptoms during MDE (intra-MDE hypomania) were systematically assessed and graded by the Hypomania Interview Guide (HIG). The frequency distributions of the HIG total scores in each of the MDD, BP-II and the combined entire sample were plotted using the kernel density estimate. Finally, bipolar family history (BFH) was investigated by structured interview (the Family History Screen).
There were 261 MDD and 389 BP-II. As in the previous smaller samples, categorically defined BP-II compared with MDD had significantly earlier age at onset, higher rates of familial bipolarity (mostly BP-II), history of MDE recurrences (>or=5), and atypical features. However, examining hypomania scores dimensionally, whether we examined the MDD, BP-II, or the combined sample, kernel density estimate distribution of these scores had a normal-like shape (i.e., no bimodality). Also, in the combined sample of MDE, we found a dose-response relationship between BFH loading and intra-MDE hypomania measured by HIG scores.
Although the interviewer (FB) could not be blind to the diagnostic status of his private patients, the systematic rigorous interview process in a very large clinical population minimized any unintended biases.
Unlike previous studies that have examined the number of DSM-IV hypomanic signs and symptoms both outside and during MDE, the present analyses relied on the more precise hypomania scores as measured by the HIG. The finding of a dose-response relationship between BFH and HIG scores in the sample at large strongly suggests a continuity between BP-II and MDD. Our data indicate that even in those clinically depressed patients without past hypomanic episodes (so-called "unipolar" MDD), such scores are normally rather than bimodally distributed during MDE. Moreover, the absence of a 'zone of rarity' in the distribution of hypomanic scores in the combined total, MDD and BP-II MDE samples, indicates that MDD and BP-II exist on a dimensional spectrum. From a nosologic perspective, our data are contrary to what one would expect from a categorical unipolar-bipolar distinction. In practical terms, intra-MDE hypomania and BFH, especially in recurrent MDD, represent strong indicators of bipolarity.
目前,单相障碍和双相障碍是完全不同还是处于同一谱系是一个备受争议的问题。我们利用正在进行的拉文纳 - 圣地亚哥合作数据库,针对重度抑郁症(MDD)和双相II型障碍(BP-II)来研究这个问题。
FB在意大利私人诊所环境中的研究人群包括连续650例出现重度抑郁发作(MDE)的门诊患者,这些患者通过针对DSM-IV的结构化临床访谈的修改版进行确诊。根据MDE时间范围之外的离散轻躁狂发作,将患者分别归入MDD或BP-II。此外,通过轻躁狂访谈指南(HIG)系统评估并分级MDE期间的轻躁狂体征和症状(MDE内轻躁狂)。使用核密度估计绘制MDD、BP-II以及合并的整个样本中HIG总分的频率分布。最后,通过结构化访谈(家族史筛查)调查双相家族史(BFH)。
有261例MDD患者和389例BP-II患者。与之前较小的样本一样,与MDD相比,明确界定的BP-II发病年龄显著更早,家族性双相障碍发生率更高(大多为BP-II),MDE复发史(≥5次)以及非典型特征更多。然而,从维度上检查轻躁狂评分时,无论我们检查的是MDD、BP-II还是合并样本,这些评分的核密度估计分布都呈正态形状(即无双峰性)。此外,在MDE的合并样本中,我们发现BFH负荷与通过HIG评分测量的MDE内轻躁狂之间存在剂量反应关系。
尽管访谈者(FB)无法对其私人患者的诊断状态保持盲态,但在非常大的临床人群中进行的系统严格访谈过程将任何意外偏差降至最低。
与之前研究MDE之外和期间DSM-IV轻躁狂体征和症状数量的研究不同,本分析依赖于HIG测量的更精确的轻躁狂评分。在整个样本中BFH与HIG评分之间存在剂量反应关系这一发现强烈表明BP-II和MDD之间存在连续性。我们的数据表明,即使在那些既往无轻躁狂发作的临床抑郁症患者(所谓的“单相”MDD)中,这些评分在MDE期间也是呈正态分布而非双峰分布。此外,在合并的总体、MDD和BP-II MDE样本中轻躁狂评分分布不存在“罕见区”,这表明MDD和BP-II存在于一个维度谱系上。从疾病分类学角度来看,我们的数据与从单相 - 双相的绝对区分所预期的情况相反。实际上,MDE内轻躁狂和BFH,特别是在复发性MDD中,是双相性的有力指标。